Peringatan Keamanan

Studies on the carcinogenicity or reproductive effects of poractant alfa have not been conducted. Mutagenicity assays were negative.
In the case of an overdose with poractant alfa where there are clear clinical effects on the infant's respiration, ventilation, or oxygenation, it is recommended that as much of the solution be aspirated as possible and the infant be managed with supportive measures. Fluid and electrolyte balances should be monitored closely in this case.

Poractant alfa

DB09113

biotech approved

Deskripsi

Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of poractant alfa has only been evaluated in animal studies. When studied in adult and newborn rabbits, the half-life in the lungs was found to be 25 and 67 respectively.
Volume Distribusi No studies on the distribution of poractant alfa have been performed in humans.
Klirens (Clearance) No studies on clearance of poractant alfa have been performed in humans.

Absorpsi

Poractant alfa is administered directly to the site of action in the lungs via endotracheal tube. It very rapidly adsorbs to the air-liquid interface to form a stable surfactant monolayer. No studies on absorption of poractant alfa have been performed in humans.

Metabolisme

No studies on the metabolism of poractant alfa have been performed in humans. One small study in rabbits did find that poractant alfa may be degraded by macrophages and that it may, in part, be recycled in the alveoli in a similar manner to endogenous lung surfactant.

Rute Eliminasi

No studies on elimination of poractant alfa have been performed in humans.

Interaksi Obat

141 Data
Ceritinib Poractant alfa may increase the bradycardic activities of Ceritinib.
Ivabradine Poractant alfa may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Poractant alfa.
Esmolol Esmolol may increase the bradycardic activities of Poractant alfa.
Betaxolol Betaxolol may increase the bradycardic activities of Poractant alfa.
Midodrine Midodrine may increase the bradycardic activities of Poractant alfa.
Pregabalin Pregabalin may increase the bradycardic activities of Poractant alfa.
Metoprolol Metoprolol may increase the bradycardic activities of Poractant alfa.
Isradipine Isradipine may increase the bradycardic activities of Poractant alfa.
Atenolol Atenolol may increase the bradycardic activities of Poractant alfa.
Diltiazem Diltiazem may increase the bradycardic activities of Poractant alfa.
Trimethadione Trimethadione may increase the bradycardic activities of Poractant alfa.
Timolol Timolol may increase the bradycardic activities of Poractant alfa.
Amlodipine Amlodipine may increase the bradycardic activities of Poractant alfa.
Digoxin Digoxin may increase the bradycardic activities of Poractant alfa.
Nimodipine Nimodipine may increase the bradycardic activities of Poractant alfa.
Nisoldipine Nisoldipine may increase the bradycardic activities of Poractant alfa.
Bendroflumethiazide Bendroflumethiazide may increase the bradycardic activities of Poractant alfa.
Sotalol Sotalol may increase the bradycardic activities of Poractant alfa.
Lercanidipine Lercanidipine may increase the bradycardic activities of Poractant alfa.
Lamotrigine Lamotrigine may increase the bradycardic activities of Poractant alfa.
Cinnarizine Cinnarizine may increase the bradycardic activities of Poractant alfa.
Propranolol Propranolol may increase the bradycardic activities of Poractant alfa.
Clonidine Clonidine may increase the bradycardic activities of Poractant alfa.
Ethosuximide Ethosuximide may increase the bradycardic activities of Poractant alfa.
Labetalol Labetalol may increase the bradycardic activities of Poractant alfa.
Bisoprolol Bisoprolol may increase the bradycardic activities of Poractant alfa.
Nicardipine Nicardipine may increase the bradycardic activities of Poractant alfa.
Dexmedetomidine Dexmedetomidine may increase the bradycardic activities of Poractant alfa.
Magnesium sulfate Magnesium sulfate may increase the bradycardic activities of Poractant alfa.
Verapamil Verapamil may increase the bradycardic activities of Poractant alfa.
Galantamine Galantamine may increase the bradycardic activities of Poractant alfa.
Tizanidine Tizanidine may increase the bradycardic activities of Poractant alfa.
Sufentanil Sufentanil may increase the bradycardic activities of Poractant alfa.
Alfentanil Alfentanil may increase the bradycardic activities of Poractant alfa.
Fentanyl Fentanyl may increase the bradycardic activities of Poractant alfa.
Levomenthol Levomenthol may increase the bradycardic activities of Poractant alfa.
Loperamide Loperamide may increase the bradycardic activities of Poractant alfa.
Donepezil Donepezil may increase the bradycardic activities of Poractant alfa.
Alprenolol Alprenolol may increase the bradycardic activities of Poractant alfa.
Remifentanil Remifentanil may increase the bradycardic activities of Poractant alfa.
Zonisamide Zonisamide may increase the bradycardic activities of Poractant alfa.
Pindolol Pindolol may increase the bradycardic activities of Poractant alfa.
Methyldopa Methyldopa may increase the bradycardic activities of Poractant alfa.
Rivastigmine Rivastigmine may increase the bradycardic activities of Poractant alfa.
Guanfacine Guanfacine may increase the bradycardic activities of Poractant alfa.
Felodipine Felodipine may increase the bradycardic activities of Poractant alfa.
Nitrendipine Nitrendipine may increase the bradycardic activities of Poractant alfa.
Perhexiline Perhexiline may increase the bradycardic activities of Poractant alfa.
Nifedipine Nifedipine may increase the bradycardic activities of Poractant alfa.
Amiodarone Amiodarone may increase the bradycardic activities of Poractant alfa.
Carvedilol Carvedilol may increase the bradycardic activities of Poractant alfa.
Bretylium Bretylium may increase the bradycardic activities of Poractant alfa.
Propafenone Propafenone may increase the bradycardic activities of Poractant alfa.
Acebutolol Acebutolol may increase the bradycardic activities of Poractant alfa.
Nadolol Nadolol may increase the bradycardic activities of Poractant alfa.
Bepridil Bepridil may increase the bradycardic activities of Poractant alfa.
Bevantolol Bevantolol may increase the bradycardic activities of Poractant alfa.
Practolol Practolol may increase the bradycardic activities of Poractant alfa.
Penbutolol Penbutolol may increase the bradycardic activities of Poractant alfa.
Mibefradil Mibefradil may increase the bradycardic activities of Poractant alfa.
Oxprenolol Oxprenolol may increase the bradycardic activities of Poractant alfa.
Nimesulide Nimesulide may increase the bradycardic activities of Poractant alfa.
Prenylamine Prenylamine may increase the bradycardic activities of Poractant alfa.
Cyclandelate Cyclandelate may increase the bradycardic activities of Poractant alfa.
Flunarizine Flunarizine may increase the bradycardic activities of Poractant alfa.
Fluspirilene Fluspirilene may increase the bradycardic activities of Poractant alfa.
Celiprolol Celiprolol may increase the bradycardic activities of Poractant alfa.
Dronedarone Dronedarone may increase the bradycardic activities of Poractant alfa.
Nebivolol Nebivolol may increase the bradycardic activities of Poractant alfa.
Lucinactant Lucinactant may increase the bradycardic activities of Poractant alfa.
Clevidipine Clevidipine may increase the bradycardic activities of Poractant alfa.
Methsuximide Methsuximide may increase the bradycardic activities of Poractant alfa.
Seletracetam Seletracetam may increase the bradycardic activities of Poractant alfa.
Nylidrin Nylidrin may increase the bradycardic activities of Poractant alfa.
Lacosamide The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Poractant alfa is combined with Lacosamide.
Calfactant Calfactant may increase the bradycardic activities of Poractant alfa.
Dotarizine Dotarizine may increase the bradycardic activities of Poractant alfa.
Pasireotide Pasireotide may increase the bradycardic activities of Poractant alfa.
Nilvadipine Nilvadipine may increase the bradycardic activities of Poractant alfa.
Bufuralol Bufuralol may increase the bradycardic activities of Poractant alfa.
Beractant Beractant may increase the bradycardic activities of Poractant alfa.
Lanreotide Lanreotide may increase the bradycardic activities of Poractant alfa.
Tranilast Tranilast may increase the bradycardic activities of Poractant alfa.
Bopindolol Bopindolol may increase the bradycardic activities of Poractant alfa.
Bupranolol Bupranolol may increase the bradycardic activities of Poractant alfa.
Agmatine Agmatine may increase the bradycardic activities of Poractant alfa.
Crizotinib Crizotinib may increase the bradycardic activities of Poractant alfa.
Fingolimod Fingolimod may increase the bradycardic activities of Poractant alfa.
Tofacitinib Tofacitinib may increase the bradycardic activities of Poractant alfa.
Regorafenib Regorafenib may increase the bradycardic activities of Poractant alfa.
Indenolol Indenolol may increase the bradycardic activities of Poractant alfa.
Fendiline Fendiline may increase the bradycardic activities of Poractant alfa.
Eperisone Eperisone may increase the bradycardic activities of Poractant alfa.
Trimebutine Trimebutine may increase the bradycardic activities of Poractant alfa.
Pinaverium Pinaverium may increase the bradycardic activities of Poractant alfa.
Arotinolol Poractant alfa may increase the bradycardic activities of Arotinolol.
Tolfenamic acid Poractant alfa may increase the bradycardic activities of Tolfenamic acid.
Barnidipine Poractant alfa may increase the bradycardic activities of Barnidipine.
Aranidipine Poractant alfa may increase the bradycardic activities of Aranidipine.

Referensi & Sumber

Synthesis reference: Curosurf: Product Monograph. Parma, Italy: Chiesi Farmaceutici S.p.A.; 2008: 25-27.
Artikel (PubMed)
  • PMID: 19956811
    Fujii AM, Carillo M: Animal-derived surfactant treatment of respiratory distress syndrome in premature neonates: a review. Drugs Today (Barc). 2009 Sep;45(9):697-709. doi: 1396674/dot.2009.45.9.1418185.
  • PMID: 25683992
    Jeon GW, Oh M, Sin JB: Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study. Yonsei Med J. 2015 Mar;56(2):433-9. doi: 10.3349/ymj.2015.56.2.433.
  • PMID: 9727777
    Alberti A, Pettenazzo A, Enzi GB, Palamidese A, Mapp C, Ventura P, Baritussio A: Uptake and degradation of Curosurf after tracheal administration to newborn and adult rabbits. Eur Respir J. 1998 Aug;12(2):294-300.
  • PMID: 9150335
    Bourbon JR, Chailley-Heu B, Gautier B: The exogenous surfactant Curosurf enhances phosphatidylcholine content in isolated type II cells. Eur Respir J. 1997 Apr;10(4):914-9.
  • PMID: 25583659
    Calkovska A, Uhliarova B, Joskova M, Franova S, Kolomaznik M, Calkovsky V, Smolarova S: Pulmonary surfactant in the airway physiology: a direct relaxing effect on the smooth muscle. Respir Physiol Neurobiol. 2015 Apr;209:95-105. doi: 10.1016/j.resp.2015.01.004. Epub 2015 Jan 10.
  • PMID: 19822594
    Cogo PE, Facco M, Simonato M, Verlato G, Rondina C, Baritussio A, Toffolo GM, Carnielli VP: Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome. Pediatrics. 2009 Nov;124(5):e950-7. doi: 10.1542/peds.2009-0126. Epub 2009 Oct 12.
  • PMID: 26690260
    Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Rojas-Reyes MX: Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2015 Dec 21;12:CD010249. doi: 10.1002/14651858.CD010249.pub2.
  • PMID: 7527760
    Wiseman LR, Bryson HM: Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome. Drugs. 1994 Sep;48(3):386-403.
Menampilkan 8 dari 13 artikel.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Curosurf
    Suspension • 80 mg/1mL • Endotracheal • US • Approved
  • Curosurf
    Suspension • 80 mg/1mL • Endotracheal • US • Approved
  • Curosurf
    Suspension • 80 mg / mL • Endotracheal • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul